Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine

Schillaci, Orazio; Scimeca, Manuel; Trivigno, Donata; Chiaravalloti, Agostino; Facchetti, Simone; Anemona, Lucia; Bonfiglio, Rita; Santeusanio, Giuseppe; Tancredi, Virginia; Bonanno, Elena; Urbano, Nicoletta; Mauriello, Alessandro

doi:10.1016/j.nucmedbio.2019.01.003

Cited by 22 publications

(10 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies emphasized the needed for innovative multidisciplinary approaches to address the new challenges of cancer medicine [15,16,17]. In particular, great relevance has been given to the collaboration between imaging diagnostics and anatomic pathology departments [17,18,19,20,21]. The comparison and sharing of data derived by imaging procedures and histopathological analysis can shed new light on cancer mechanisms, thus providing useful information for the development and/or revaluation of diagnostic analyses.…”

Section: Discussionmentioning

confidence: 99%

18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

Urbano

Scimeca

Crocco

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

The main aim of this study was to investigate the possible association between 18F–choline uptake and histopathological features of prostate biopsies such as the Gleason Group and the expression of both epithelial to mesenchymal transition (vimentin) and bone mineralization (bone morphogenetics protein (BMP)-2, runt-related transcription factor 2 (RUNX2), receptor activator of nuclear factor-κB ligand (RANKL), vitamin D receptor (VDR), and pentraxin 3 (PTX3) in situ biomarkers. To this end, we enrolled 79 consecutive prostate cancer patients that underwent both the 18F–choline PET/CT analysis and the prostate bioptic procedure. The standardized uptake value (SUV) average values were collected from 18F–choline PET/CT analysis whereas Gleason Group and immunostaining data were collected from paraffin-embedded sections. Histological classification showed a heterogenous population including both low/intermediate and high-grade prostate cancers. A significant increase of 18F–choline uptake in high-grade prostate lesions (Gleason Score ≥8) was found. Also, linear regression analysis showed a significant correlation between 18F–choline uptake and the number of vimentin, RANKL, VDR, or PTX3 positive prostate cancer cells. Conversely, we observed no significant association between 18F–choline uptake and the expression of bone biomarkers involved in the early phases of osteoblast differentiation (BMP-2, RUNX2). In conclusion, results here reported can lay the foundation for the use of 18F–choline positron emission tomography (PET)/computed tomography (CT) as a diagnostic tool capable of identifying high-grade prostate cancer lesions expressing bone biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

Urbano

Scimeca

Crocco

et al. 2019

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inflammation is the major etiology behind the development of prostate cancer. Acute or chronic inflammation can result in not only carcinogenesis but also progression of prostate cancer [9,10,11,12]. Inflammation in prostate cancer is linked to various factors including infection [13], microbiome [14], obesity [15], and high-fat diet (HFD) [16].…”

Section: Introductionmentioning

confidence: 99%

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer

Hayashi

Fujita

Matsushita

et al. 2019

Cancers

View full text Add to dashboard Cite

Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. Interventions by medications and diets to control systemic and/or local inflammation might be effective therapies for prostate cancer progression. Epidemiological investigations and basic research using human immune cells or mouse models have revealed that non-steroidal anti-inflammatory drugs, metformin, statins, soy isoflavones, and other diets are potential interventions for preventing progression of prostate cancer by suppressing inflammation. It is essential to evaluate appropriate indications and doses of each drug and diet.

show abstract

“…Additionally, it contributes to minimizing expenditure on medication development and animal use in preclinical toxicological research. In order to determine whether the drug concentration delivered to the target is sufficient to elicit a pharmacologic response, the PET imaging protocol can be used to measure both AR levels (in the sense of a predictive biomarker for estimating response to therapy and monitoring drug-target engagement) and AR activity using a PD biomarker [ 1 , 12 , 21 , 52 , 58 , 72 , 73 , 75 , 78 , 79 , 87 , 89 , 90 , 91 , 92 ].…”

Section: Positron Emission Tomography (Pet)mentioning

confidence: 99%

The Role of Molecular Imaging in Personalized Medicine

Salih

Elliyanti

Alkatheeri³

et al. 2023

JPM

View full text Add to dashboard Cite

The concept of personalized medicine refers to the tailoring of medical treatment to each patient’s unique characteristics. Scientific advancements have led to a better understanding of how a person’s unique molecular and genetic profile makes them susceptible to certain diseases. It provides individualized medical treatments that will be safe and effective for each patient. Molecular imaging modalities play an essential role in this aspect. They are used widely in screening, detection and diagnosis, treatment, assessing disease heterogeneity and progression planning, molecular characteristics, and long-term follow-up. In contrast to conventional imaging approaches, molecular imaging techniques approach images as the knowledge that can be processed, allowing for the collection of relevant knowledge in addition to the evaluation of enormous patient groups. This review presents the fundamental role of molecular imaging modalities in personalized medicine.

show abstract

Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine

Cited by 22 publications

References 160 publications

18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer

The Role of Molecular Imaging in Personalized Medicine

Contact Info

Product

Resources

About